Procore signs multi-year strategic collaboration agreement with AWS
Jolanda Howe, the Senior Vice President and Global Controller at Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), recently sold a significant portion of her holdings in the company. According to a recent SEC filing, Howe sold 2,415 shares of common stock on March 18, 2025, at a weighted average price of $44.4484 per share. The total transaction value amounted to $107,342. The transaction comes as the $2.3 billion market cap company has seen its stock surge 74% over the past year, according to InvestingPro data.
Following the sale, Howe retains ownership of 2,426 shares in the pharmaceutical company. The transaction was executed under a Rule 10b5-1 trading plan, which was adopted by Howe on December 16, 2024. This plan allows insiders to sell a predetermined number of shares at a predetermined time, thereby helping to avoid potential accusations of insider trading. InvestingPro analysis shows the company maintains a "Good" financial health score, with analysts setting price targets ranging from $54 to $74 per share. Get access to 8 more exclusive InvestingPro Tips and comprehensive analysis with a subscription.
The sale occurred within a price range of $44.21 to $44.91 per share, and further details regarding the number of shares sold at each price are available upon request to the SEC or the company. The company has demonstrated strong revenue growth of 81% in the last twelve months, with current trading levels near its 52-week high of $54.23.
In other recent news, Mirum Pharmaceuticals reported fourth-quarter earnings that did not meet analyst expectations, with an adjusted loss of $1.85 per share, significantly wider than the forecasted $0.30 loss. Despite this, the company saw a revenue increase to $99.41 million, surpassing the consensus estimate of $95.4 million and marking a 55.6% rise year-over-year. For the full year 2024, Mirum’s total net product sales reached $336.4 million, a substantial increase from $178.9 million in 2023. Looking ahead, Mirum has provided 2025 guidance for global net product sales between $420 million and $435 million, suggesting continued growth. H.C. Wainwright raised the price target for Mirum to $72, maintaining a Buy rating, highlighting the company’s expected positive cash flow in 2025. The analyst firm noted Mirum’s progress with its LIVMARLI drug and anticipated growth in its bile acid product portfolio. Additionally, Mirum is advancing its clinical development programs, including the Phase 3 EXPAND study of LIVMARLI and the Phase 2 VISTAS study of volixibat. These developments are expected to contribute to Mirum’s future growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.